A multi-kinase inhibitor; inhibits TrkA

TPX-0005 – 25 mg

Brand:
Cayman
CAS:
1802220-02-5
Storage:
-20
UN-No:
De Minimis - 3077 / 9

TPX-0005 is a multi-kinase inhibitor that inhibits TrkA, TrkB, and TrkC (IC50s = 0.83, 0.05, and 0.1 nM, respectively) as well as C-ros oncogene 1 (ROS1; IC50 = 0.07 nM).{36850} It inhibits a variety of other kinases, including ALK, JAK2, LYN, Src, and FAK (IC50s = 1.04, 1.04, 1.66, 5.3, and 6.96 nM, respectively). It inhibits proliferation of PC-9, H1975, 11-18, HCC4006, and HCC827 lung cancer cells (IC50s = 100, 100, 150, 148, and 430 nM, respectively) with additive or synergistic effects when used in combination with gefitinib (Item No. 13166), afatinib (Item No. 11492), PF-299804 (dacomitinib; Item No. 9001879), or osimertinib. TPX-0005 (30 mg/kg) reduces tumor growth in PC-9 and H1975 mouse xenograft models and potentiates the effect of osimertinib in these models.  

 

Available on backorder

Add to quotes
SKU: 23397 - 25 mg Category:

Description

A multi-kinase inhibitor; inhibits TrkA, TrkB, and TrkC (IC50s = 0.83, 0.05, and 0.1 nM, respectively) as well as ROS1 (IC50 = 0.07 nM); inhibits a variety of other kinases, including ALK, JAK2, LYN, Src, and FAK (IC50s = 1.04, 1.04, 1.66, 5.3, and 6.96 nM, respectively); inhibits proliferation of PC-9, H1975, 11-18, HCC4006, and HCC827 cells (IC50s = 100, 100, 150, 148, and 430 nM, respectively) with additive or synergistic effects when used in combination with certain compounds, including osimertinib; reduces tumor growth in PC-9 and H1975 mouse xenograft models; potentiates the effect of osimertinib on tumor growth in vivo

Formal name: (7S,13R)-11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-1,15-etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one

Synonyms: 

Molecular weight: 355.4

CAS: 1802220-02-5

Purity: ≥98%

Formulation: A crystalline solid

Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|ALK (Activin-like Kinase) Signaling||Research Area|Cancer|Cell Signaling|JAK/STAT Signaling||Research Area|Cancer|Cell Signaling|SRC Family Signaling

Related products

  • A zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers

    1,2-Dipalmitoyl-sn-glycero-3-PC – 250 mg

    1,2-Dipalmitoyl-sn-glycero-3-PC (DPPC) is a zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers, bilayers, and liposomes for use in a variety of applications.{14480,24261,14478,14479} It has been used in the formation of proteoliposomes for implantation of γ-glutamyl transpeptidase into human erythrocyte membranes.{14478} Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice.{14479}  

     

    Brand:
    Cayman
    SKU:10009473 - 250 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page
  • A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H

    (R)-Roscovitine – 10 mg

    Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}  

     

    Brand:
    Cayman
    SKU:10009569 - 10 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page
  • A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H

    (R)-Roscovitine – 5 mg

    Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}  

     

    Brand:
    Cayman
    SKU:10009569 - 5 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page
  • CAY10512 is a substituted trans-stilbene analog of resveratrol that is 100-fold more potent as measured by antioxidant activity. The IC50 value for inhibition of TNFα-induced activation of NF-κB by CAY10512 is 0.15 µM compared to 20 µM by resveratrol.{14545}

    CAY10512 – 10 mg

    The nuclear factor-κB (NF-κB) regulates the expression of numerous genes involved in immunity and inflammation, cellular stress responses, growth, and apoptosis. Resveratrol, a polyphenolic trans-stilbene, is a known inhibitor of the activation of NF-κB and exhibits activity against a wide variety of cancer cells. CAY10512 is a substituted trans-stilbene analog of resveratrol that is 100-fold more potent as measured by antioxidant activity. The IC50 value for inhibition of TNFα-induced activation of NF-κB by CAY10512 is 0.15 µM compared to 20 µM by resveratrol.{14545}  

     

    Brand:
    Cayman
    SKU:10009536 - 10 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page